Scholarlink

<p>Angiopoietin 2 (Ang-2) is a growth factor in angiogenesis, causing pericyte migration and vascular regression, leading to increased vascular permeability. Inflammatory mediators, hypoxia, hyperglycaemia and cancer stimulate its secretion. Particularly in sepsis, high Ang-2 levels appear to be a prognostic marker for morbidity and mortality in the critically ill. As an important trigger for endothelial damage one therapeutic option in these patients might be the removal of Ang-2. The Cyto-SOLVE trial included patients with septic shock or rhabdomyolsis treated with the adsorber Cytosorb (CS) (included in continuous kidney replacement therapy) for the removal of cytokines and myoglobin. Ang-2 was measured in the patient´s blood and pre- and post-CS at defined time points (ten minutes, one, three, six, and twelve hours after initiation). Ang-2 extracorporeal clearances (ml/min) were calculated with: <InlineEquation ID="IEq1"> <InlineMediaObject> <ImageObject Color="BlackWhite" FileRef="41598_2025_21215_Article_IEq1.gif" Format="GIF" Height="33" Rendition="HTML" Resolution="72" Type="Linedraw" Width="403" /> </InlineMediaObject> <EquationSource Format="TEX">\(\:\left(bloodflow*\left(1-hematocrit\right)\right)*\left(\frac{concentration\:\left(pre-post\right)}{concentration\:\left(pre\right)}\right).\)</EquationSource> </InlineEquation> <i>U</i>-Test was used to compare different subgroups. 26 patients were included (17 with rhabdomyolsis and 9 with septic shock, median Ang-2 concentration prior to CS-application: 21,653 pg/ml). We observed a low Ang-2 adsorption in the first hour of CS application, resulting in a median Ang-2 extracorporeal clearance of 8.2&#xa0;ml/min and 1.7&#xa0;ml/min after 10&#xa0;min and 1&#xa0;h, respectively. There was no significant change in Ang-2 plasma concentrations at any time point. No significant difference in Ang-2 levels was observed between patients with septic shock (median: 31,916 pg/ml) and rhabdomyolysis (median 18,379 pg/ml, <i>p</i> = 0.241). The Cytosorb adsorber does not decrease Ang-2 concentrations by adsorption. Therefore, Ang-2 can be considered a reliable biomarker for endothelial dysfunction even in the presence of Cytosorb therapy in critically ill patients. Further studies should be conducted to determine whether the removal of Ang-2 could be beneficial when utilizing an appropriate device.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Angiopoietin-2 adsorption attempt with the cytokine adsorber cytosorb in critically ill patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月1日

查看全文
  • Helen Graf,
  • Caroline Gräfe,
  • Michael Paal,
  • Katarina Habler,
  • Alice Ewert,
  • Wolfgang Wilfert,
  • Uwe Liebchen,
  • Martin Bender,
  • Danilo Hackner,
  • Christina Scharf

摘要

Angiopoietin 2 (Ang-2) is a growth factor in angiogenesis, causing pericyte migration and vascular regression, leading to increased vascular permeability. Inflammatory mediators, hypoxia, hyperglycaemia and cancer stimulate its secretion. Particularly in sepsis, high Ang-2 levels appear to be a prognostic marker for morbidity and mortality in the critically ill. As an important trigger for endothelial damage one therapeutic option in these patients might be the removal of Ang-2. The Cyto-SOLVE trial included patients with septic shock or rhabdomyolsis treated with the adsorber Cytosorb (CS) (included in continuous kidney replacement therapy) for the removal of cytokines and myoglobin. Ang-2 was measured in the patient´s blood and pre- and post-CS at defined time points (ten minutes, one, three, six, and twelve hours after initiation). Ang-2 extracorporeal clearances (ml/min) were calculated with: \(\:\left(bloodflow*\left(1-hematocrit\right)\right)*\left(\frac{concentration\:\left(pre-post\right)}{concentration\:\left(pre\right)}\right).\) U-Test was used to compare different subgroups. 26 patients were included (17 with rhabdomyolsis and 9 with septic shock, median Ang-2 concentration prior to CS-application: 21,653 pg/ml). We observed a low Ang-2 adsorption in the first hour of CS application, resulting in a median Ang-2 extracorporeal clearance of 8.2 ml/min and 1.7 ml/min after 10 min and 1 h, respectively. There was no significant change in Ang-2 plasma concentrations at any time point. No significant difference in Ang-2 levels was observed between patients with septic shock (median: 31,916 pg/ml) and rhabdomyolysis (median 18,379 pg/ml, p = 0.241). The Cytosorb adsorber does not decrease Ang-2 concentrations by adsorption. Therefore, Ang-2 can be considered a reliable biomarker for endothelial dysfunction even in the presence of Cytosorb therapy in critically ill patients. Further studies should be conducted to determine whether the removal of Ang-2 could be beneficial when utilizing an appropriate device.